NO20065326L - Aminopyridin-derivater som selektive dopamin D3 agonister - Google Patents

Aminopyridin-derivater som selektive dopamin D3 agonister

Info

Publication number
NO20065326L
NO20065326L NO20065326A NO20065326A NO20065326L NO 20065326 L NO20065326 L NO 20065326L NO 20065326 A NO20065326 A NO 20065326A NO 20065326 A NO20065326 A NO 20065326A NO 20065326 L NO20065326 L NO 20065326L
Authority
NO
Norway
Prior art keywords
disorder
agonists
compounds
sexual dysfunction
female
Prior art date
Application number
NO20065326A
Other languages
English (en)
Norwegian (no)
Inventor
Charlotte Moira Norfo Allerton
David Hepworth
Andrew Simon Cook
Duncan Charles Miller
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065326(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0411891A external-priority patent/GB0411891D0/en
Priority claimed from GB0412463A external-priority patent/GB0412463D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20065326L publication Critical patent/NO20065326L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20065326A 2004-05-27 2006-11-20 Aminopyridin-derivater som selektive dopamin D3 agonister NO20065326L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0411891A GB0411891D0 (en) 2004-05-27 2004-05-27 New aminopyridine derivatives and their use as pharmaceuticals
GB0412463A GB0412463D0 (en) 2004-06-03 2004-06-03 New aminopyridine derivatives and their use as pharmaceuticals
PCT/IB2005/001554 WO2005115985A1 (fr) 2004-05-27 2005-05-17 Derives d'aminopyridine utilises comme agonistes selectifs de la dopamine d3

Publications (1)

Publication Number Publication Date
NO20065326L true NO20065326L (no) 2006-12-19

Family

ID=34970000

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065326A NO20065326L (no) 2004-05-27 2006-11-20 Aminopyridin-derivater som selektive dopamin D3 agonister

Country Status (21)

Country Link
EP (1) EP1758862A1 (fr)
JP (1) JP4198183B2 (fr)
AP (1) AP2006003824A0 (fr)
AR (1) AR049548A1 (fr)
AU (1) AU2005247699A1 (fr)
BR (1) BRPI0511571A (fr)
CA (1) CA2567935C (fr)
EA (1) EA200601982A1 (fr)
EC (1) ECSP067029A (fr)
GT (1) GT200500125A (fr)
IL (1) IL179314A0 (fr)
MA (1) MA28607B1 (fr)
MX (1) MXPA06013786A (fr)
NL (1) NL1029139C2 (fr)
NO (1) NO20065326L (fr)
PA (1) PA8635101A1 (fr)
PE (1) PE20060366A1 (fr)
SV (1) SV2005002129A (fr)
TW (1) TW200609216A (fr)
UY (1) UY28925A1 (fr)
WO (1) WO2005115985A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502509D0 (en) 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
JP5777526B2 (ja) * 2009-02-13 2015-09-09 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 縮合ピリミジン類
ES2552166T3 (es) * 2010-04-12 2015-11-26 Supernus Pharmaceuticals, Inc. Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas
JP6075654B2 (ja) 2011-06-30 2017-02-08 ドナルドソン カンパニー，インコーポレイティド 空気／油分離装置アセンブリ、部品及び方法
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
CN109641871B (zh) 2016-07-20 2021-10-22 诺华股份有限公司 氨基吡啶衍生物及其作为选择性alk-2抑制剂的用途
AU2020270992A1 (en) * 2019-04-12 2021-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
IL293085A (en) 2019-11-22 2022-07-01 Incyte Corp Combined treatment that includes an alk2 inhibitor and a jak2 inhibitor
TW202214239A (zh) 2020-06-16 2022-04-16 美商英塞特公司 用於治療貧血之alk2抑制劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) * 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
RS51442B (en) * 2002-12-10 2011-04-30 Pfizer Inc. MORPHOLINE DERIVATIVES USED AS DOPAMINE AGONISTS IN TREATMENT I.A. SEXUAL DYSFUNCTIONS

Also Published As

Publication number Publication date
JP2008500331A (ja) 2008-01-10
AR049548A1 (es) 2006-08-16
AP2006003824A0 (en) 2006-12-31
UY28925A1 (es) 2005-12-30
ECSP067029A (es) 2006-12-29
IL179314A0 (en) 2007-03-08
EA200601982A1 (ru) 2007-04-27
PE20060366A1 (es) 2006-05-15
CA2567935A1 (fr) 2005-12-08
AU2005247699A1 (en) 2005-12-08
TW200609216A (en) 2006-03-16
NL1029139A1 (nl) 2005-11-30
JP4198183B2 (ja) 2008-12-17
PA8635101A1 (es) 2006-05-16
NL1029139C2 (nl) 2006-06-19
EP1758862A1 (fr) 2007-03-07
WO2005115985A1 (fr) 2005-12-08
BRPI0511571A (pt) 2008-01-02
GT200500125A (es) 2006-01-10
SV2005002129A (es) 2005-12-13
MXPA06013786A (es) 2007-01-25
CA2567935C (fr) 2009-10-27
MA28607B1 (fr) 2007-05-02

Similar Documents

Publication Publication Date Title
NO20065326L (no) Aminopyridin-derivater som selektive dopamin D3 agonister
GEP20217265B (en) Glp-1 receptor agonists and uses thereof
DE60205465D1 (de) Piperazinderivate als agonisten des melanocortin-rezeptors
CY1110014T1 (el) Παραγωγα τετραϋδροκαρβαζολιου χρησιμα ως τροποποιητες υποδοχεα ανδρογονων (sarm)
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
MA40481A (fr) Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante
ATE342057T1 (de) Melanocortinrezeptoragonisten
MX369880B (es) Sistema y metodo para servicio de una perforacion de pozo.
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
EA201101524A1 (ru) Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
MX2015007796A (es) Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales.
SG2013049648A (en) Chlorination of carbohydrates and carbohydrate derivatives
CL2012003132A1 (es) Compuestos derivados de heteroaril-ciclohexil-tetraazabenzo[e]azulenos, antagonistas del receptor de la vla; proceso de preparacion; composicion farmaceutica; y su uso para la prevencion o tratamiento de dismenorrea, disfuncion sexual masculina o femenina, hipertension y cirrosis hepatica, entre otros.
NO20092143L (no) Anvendelse av testosteron og en 5-HT1A-agonist ved behandling av seksuell dysfunksjon
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
GT200600207A (es) Proceso para la síntesis de compuestos orgánicos
PE20220811A1 (es) Procesos e intermediario para la preparacion a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparacion de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida
NO20065328L (no) Indazol- og indolon-derivarter, og anvendelse av disse som farmasoytiske midler.
MA33500B1 (fr) Dérivés de pyrazoles, leur préparation et leur application en thérapeutique
EA200801211A1 (ru) Производные 9-хлор-15-простагландина, способ их получения и использования в лекарственных препаратах
TW200716555A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
MA46064A (fr) Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
DOP2005000095A (es) Nuevos derivados de aminopiridina y su uso como farmacos
MX2012014968A (es) Dosis fija de una combinacion farmaceutica de tadalafilo y dapoxetina.
DOP2005000093A (es) Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos